FOXA1 and cervical carcinoma: In their study, Xie et al. discovered that empagliflozin can suppress the development and progression of cervical cancer by activating the adenosine monophosphate (AMP)-activated protein kinase (AMPK) signaling pathway and downregulating the expression of forkhead Box A1 (FOXA1) and sonic hedgehog (SHH) (Fig. 1) [17].